8-K: Lineage Cell Therapeutics Announces First Quarter 2024 Financial Results and Business Update

Lineage Cell Therapeutics reported its first quarter 2024 financial results, highlighted by a new services agreement with Genentech and progress in its clinical programs.

Summary

• Lineage Cell Therapeutics reported a net loss of $6.5 million for the first quarter of 2024, or $0.04 per share, compared to a net loss of $4.4 million, or $0.03 per share, for the same period in 2023.
• Total revenue for the quarter was $1.4 million, a decrease of $1.0 million compared to $2.4 million in the first quarter of 2023, primarily due to lower collaboration and licensing revenue.
• Operating expenses decreased by $0.9 million to $8.1 million, with research and development expenses decreasing by $1.2 million to $3.0 million, and general and administrative expenses increasing by $0.3 million to $5.0 million.
• The company's cash, cash equivalents, and marketable securities totaled $43.6 million as of March 31, 2024, which is expected to fund operations into the third quarter of 2025.
• Lineage established a new services agreement with Genentech to support the ongoing development of the OpRegen program, with Genentech fully funding the additional services.
• The company is preparing to start a clinical study for its second cell transplant program, OPC1, this year.
• Positive clinical data from the OpRegen Phase 1/2a study showed a mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients, with greater gains among patients with improved outer retinal structure (+7.4 letters).

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive clinical progress and a new partnership, but also increased losses and decreased revenue. The sentiment is neutral to slightly negative due to the financial results.

Positives

• Lineage secured a new services agreement with Genentech, demonstrating continued commitment to the OpRegen program.
• Genentech will fully fund additional services related to the OpRegen program, reducing Lineage's financial burden.
• Positive long-term clinical data for OpRegen was presented, showing visual benefits from a single administration.
• The company is progressing with the start-up activities for the OPC1 clinical study.
• Lineage received a CIRM grant to support the 2nd Annual Spinal Cord Injury Investor Symposium.
• The company appointed Dr. Charlotte Hubbert as Vice President of Corporate Development, bringing valuable industry experience.
• Cash reserves are expected to support operations into Q3 2025.

Negatives

• The company experienced a net loss of $6.5 million in Q1 2024, which is higher than the $4.4 million loss in Q1 2023.
• Total revenue decreased by $1.0 million compared to the same period last year, primarily due to lower collaboration and licensing revenue.
• The net loss per share increased from $0.03 to $0.04 year-over-year.
• General and administrative expenses increased by $0.3 million compared to the same period last year.

Risks

• The company may need to allocate cash to unexpected events, potentially using cash reserves more quickly than anticipated.
• Clinical trials may not progress as expected due to factors within and outside of the company's control.
• Positive findings in early studies may not predict success in later clinical trials.
• OpRegen may not provide durable improvements in dry-AMD patients.
• Competing therapies could negatively impact the commercial potential of OpRegen.
• Roche and Genentech may not successfully advance OpRegen or obtain regulatory approval.
• The ongoing Israel-Hamas war could impact manufacturing processes.
• Lineage may not be able to manufacture sufficient clinical quantities of its product candidates.

Future Outlook

The company expects its current cash reserves to support planned operations into the third quarter of 2025 and plans to bring its second cell transplant program, OPC1, into the clinic this year.

Management Comments

• Brian M. Culley, Lineage CEO, stated that the quarter was highlighted by significant milestones and data updates on their lead program.
• Brian M. Culley also mentioned that the new services agreement with Genentech reflects an additional commitment by Genentech for the benefit of the OpRegen program.
• The CEO believes the agreement will enable their partners to take advantage of their cell transplant expertise to more fully investigate the promising potential of the OpRegen program in a cost-effective manner.

Industry Context

This announcement reflects the ongoing interest and investment in cell therapy development, particularly in areas with unmet medical needs such as geographic atrophy and spinal cord injuries. The collaboration with Genentech highlights the potential of Lineage's technology and the broader trend of pharmaceutical companies partnering with biotech firms to advance novel therapies.

Comparison to Industry Standards

• Lineage's OpRegen program is competing with other therapies in development for geographic atrophy, such as Apellis's Syfovre and Iveric Bio's Izervay, both of which have received FDA approval.
• The reported mean BCVA gain of 5.5 letters at 24 months in Cohort 4 patients in the OpRegen study is a positive result, but needs to be compared to the efficacy data of other treatments in the same patient population.
• The company's cash runway into Q3 2025 is a positive sign, but it is important to compare this to the cash burn rates and funding needs of similar biotech companies in the cell therapy space.
• The new services agreement with Genentech is a positive development, but the financial terms and the impact on Lineage's long-term revenue potential need to be analyzed in comparison to other similar collaborations in the industry.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue, but encouraged by the new Genentech agreement and clinical progress.
• Employees may be positively impacted by the company's continued progress and new partnership.
• Patients with geographic atrophy and spinal cord injuries may benefit from the development of OpRegen and OPC1.
• The company's suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Lineage will continue to execute its collaboration with Roche and Genentech.
• The company will prepare for the start of the DOSED clinical study for OPC1.
• Lineage will host the 2nd Annual Spinal Cord Injury Investor Symposium on June 26 and 27, 2024.

Key Dates

Keywords

cell therapy, OpRegen, OPC1, Genentech, Roche, clinical trial, geographic atrophy, spinal cord injury, biotechnology, financial results